News

The company expects lab results, pharmacokinetic studies, and analysis to take about two months. If the results shows bioequivalence of Prurisol with Abacavir Sulfate, Cellceutix will then schedule

Additionally, the company had recently received a Notice of Allowance from the US Patent & Trademark Office for its Emesyl trademark. The NDC number and trademark Notice of

The drug is the generic version of Celebrex, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and for the

As part of the deal, REGENX has granted Voyager a non-exclusive worldwide license, as well as sublicensing rights, to its NAV vectors for the treatment of ALS, FA

A twenty-five percent reduction in the risk of recurrence or death was observed (HR = 0.75; 95% CI = 0.64-0.90; p = 0.0013). At three years, an estimated

By using its T-cell receptor (TCR) engineering technology, Adaptimmune has created TCRs which are deployed to target the cancer testis antigen, NY-ESO-1, and other targets. The company’s trials

OsoBio is recognized as a premier contract manufacturer of highly complex injectable drug products, including sterile liquid, suspension and lyophilized formulations. The acquisition and associated fees are expected

As previously stated, Alexion believes that it has identified the process component that resulted in the presence of the visible particles and implemented a change to the process.

Theravance, Inc., A Royalty Management Company, is focused on maximizing the potential value of the respiratory assets partnered with GlaxoSmithKline plc including RELVAR/BREO ELLIPTA and ANORO ELLIPTA and